The Application of Biomarkers in the Care of Patients With Atrial Fibrillation
From 2020 to 2023, we established a longitudinal AF patient cohort with comprehensive clinical data collection. In our previous work, we utilized the Milliplex platform to screen 52 circulating biomarkers and identified several candidates potentially associated with AF burden. Building on these findings, the present study aims to further validate these biomarkers in a larger subset of patients (n=266) who completed paired pre- and post-intervention sampling. Targeted biomarkers may include NT-proBNP, IL-6, hs-CRP, Adipsin, GDF-15, sST-2, FABP3, and IGF-BP3.
Our goal is to identify markers associated with AF burden, assess their predictive performance and subgroup consistency, and further elucidate the underlying pathophysiological mechanisms.
연구 개요
상세 설명
With an aging population and advances in medical care, the prevalence of atrial fibrillation (AF) continues to rise. Although the introduction of novel oral anticoagulants has reduced the risk of stroke, AF can still lead to myocardial ischemia, fibrosis, and ultimately heart failure and valvular dysfunction. Given its often paroxysmal nature, the diagnosis and assessment of AF burden remain challenging and frequently rely on prolonged electrocardiographic monitoring.
Identifying accessible and reliable blood-based biomarkers could provide a cost-effective alternative to time-consuming and expensive wearable or implantable monitoring devices, offering significant clinical value.
연구 유형
연락처 및 위치
연구 장소
-
-
-
Taipei, 대만, 100
- National Taiwan University Hospita
-
-
참여기준
자격 기준
공부할 수 있는 나이
- 성인
- 고령자
건강한 자원 봉사자를 받아들입니다
샘플링 방법
연구 인구
설명
Inclusion Criteria:
-Who have signed up for the Protocol No. 202003090RINA(National Taiwan University Hospital Atrial Fibrillation Integrated Care Pilot Program)
Exclusion Criteria:
-Subjects without complete pre- and post-treatment testing
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
코호트 및 개입
그룹/코호트 |
|---|
|
afib
From 2020 to 2023, we established a longitudinal AF patient cohort with comprehensive clinical data collection. In our previous work, we utilized the Milliplex platform to screen 52 circulating biomarkers and identified several candidates potentially associated with AF burden. Building on these findings, the present study aims to further validate these biomarkers in a larger subset of patients (n=266) who completed paired pre- and post-intervention sampling. Targeted biomarkers may include NT-proBNP, IL-6, hs-CRP, Adipsin, GDF-15, sST-2, FABP3, and IGF-BP3. Our goal is to identify markers associated with AF burden, assess their predictive performance and subgroup consistency, and further elucidate the underlying pathophysiological mechanisms. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Novel biomarkers
기간: 1YEARS
|
Whether novel biomarkers are associated with atrial fibrillation burden and could serve as tools to assist clinicians in diagnosing and treating patients, including tracking treatment effectiveness or the timeline for progression to heart failure;
|
1YEARS
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
심방세동에 대한 임상 시험
-
Assistance Publique - Hôpitaux de Paris아직 모집하지 않음과도한 Supraventricular Ectopies 또는 Short Atrial Runs(ESVEA)
-
University of Pennsylvania빼는전형적인 심방 조동 | Atrial Flutter의 향후 개발 위험 요소미국